These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11099465)

  • 1. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression.
    Elkin M; Miao HQ; Nagler A; Aingorn E; Reich R; Hemo I; Dou HL; Pines M; Vlodavsky I
    FASEB J; 2000 Dec; 14(15):2477-85. PubMed ID: 11099465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
    Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I
    Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition.
    Taras D; Blanc JF; Rullier A; Dugot-Senant N; Laurendeau I; Bièche I; Pines M; Rosenbaum J
    Neoplasia; 2006 Apr; 8(4):312-8. PubMed ID: 16756723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
    Elkin M; Ariel I; Miao HQ; Nagler A; Pines M; de-Groot N; Hochberg A; Vlodavsky I
    Cancer Res; 1999 Aug; 59(16):4111-8. PubMed ID: 10463616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth inhibition of prostate cancer xenografts by halofuginone.
    Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
    Prostate; 2002 May; 51(2):73-83. PubMed ID: 11948962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone.
    Nagler A; Ohana M; Shibolet O; Shapira MY; Alper R; Vlodavsky I; Pines M; Ilan Y
    Eur J Cancer; 2004 Jun; 40(9):1397-403. PubMed ID: 15177499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
    Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells.
    Leiba M; Cahalon L; Shimoni A; Lider O; Zanin-Zhorov A; Hecht I; Sela U; Vlodavsky I; Nagler A
    J Leukoc Biol; 2006 Aug; 80(2):399-406. PubMed ID: 16769768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells.
    Tsai MY; Yang RC; Wu HT; Pang JH; Huang ST
    Cancer Lett; 2011 Nov; 310(2):198-206. PubMed ID: 21788102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The angiosuppressive effects of 20(R)- ginsenoside Rg3.
    Yue PY; Wong DY; Wu PK; Leung PY; Mak NK; Yeung HW; Liu L; Cai Z; Jiang ZH; Fan TP; Wong RN
    Biochem Pharmacol; 2006 Aug; 72(4):437-45. PubMed ID: 16793023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nafoxidine modulates the expression of matrix-metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in endothelial cells.
    De Lorenzo MS; Alonso DF; Gomez DE
    Anticancer Res; 2000; 20(1A):395-400. PubMed ID: 10769686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro.
    Montesano R; Kumar S; Orci L; Pepper MS
    Lab Invest; 1996 Aug; 75(2):249-62. PubMed ID: 8765325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel function of ascorbic acid as an angiostatic factor.
    Ashino H; Shimamura M; Nakajima H; Dombou M; Kawanaka S; Oikawa T; Iwaguchi T; Kawashima S
    Angiogenesis; 2003; 6(4):259-69. PubMed ID: 15166494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
    Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
    Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
    Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
    Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic function of tocotrienol.
    Miyazawa T; Shibata A; Nakagawa K; Tsuzuki T
    Asia Pac J Clin Nutr; 2008; 17 Suppl 1():253-6. PubMed ID: 18296349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor.
    Morais C; Gobe G; Johnson DW; Healy H
    Angiogenesis; 2009; 12(4):365-79. PubMed ID: 19882112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vernolide-A inhibits tumour specific angiogenesis by regulating proinflammatory cytokines, VEGF, MMPs and TIMP.
    Pratheeshkumar P; Kuttan G
    Eur J Pharmacol; 2011 Apr; 656(1-3):10-8. PubMed ID: 21256125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.